Jasper Therapeutics (JSPR) Stock Forecast, Price Target & Predictions
JSPR Stock Forecast
Jasper Therapeutics stock forecast is as follows: an average price target of $34.75 (represents a 70.09% upside from JSPR’s last price of $20.43) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
JSPR Price Target
The average price target for Jasper Therapeutics (JSPR) is $34.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $3.00. This represents a potential 70.09% upside from JSPR's last price of $20.43.
JSPR Analyst Ratings
According to 9 Wall Street analysts, Jasper Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JSPR stock is 0 'Strong Buy' (0.00%), 9 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Jasper Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 06, 2024 | Emily Bodnar | H.C. Wainwright | $65.00 | $24.52 | 165.09% | 218.16% |
| Apr 03, 2024 | Gavin Clark-Gartner | Evercore ISI | $65.00 | $26.20 | 148.09% | 218.16% |
| Feb 07, 2023 | - | Cantor Fitzgerald | $6.00 | $1.92 | 212.50% | -70.63% |
| Jan 11, 2023 | - | Credit Suisse | $3.00 | $1.65 | 81.82% | -85.32% |
The latest Jasper Therapeutics stock forecast, released on May 06, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $65.00, which represents a 165.09% increase from the stock price at the time of the forecast ($24.52), and a 218.16% increase from JSPR last price ($20.43).
Jasper Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $65.00 |
| Last Closing Price | $20.43 | $20.43 | $20.43 |
| Upside/Downside | -100.00% | -100.00% | 218.16% |
In the current month, the average price target of Jasper Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Jasper Therapeutics's last price of $20.43. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 14, 2024 | BTIG | Buy | Buy | Hold |
| Oct 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 09, 2024 | JMP Securities | - | Outperform | Initialise |
| Aug 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 08, 2024 | BTIG | - | Buy | Initialise |
| Jun 25, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 06, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 03, 2024 | Evercore ISI | - | Outperform | Initialise |
Jasper Therapeutics's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave JSPR a "Buy" rating, the same as its previous rate.
Jasper Therapeutics Financial Forecast
Jasper Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. JSPR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Jasper Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict JSPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Jasper Therapeutics's previous annual EBITDA (undefined) of $NaN.
Jasper Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-16.78M | $-16.19M | $-15.84M | $-15.27M | $-21.26M | $-19.88M | $-19.43M | $-18.49M | $-18.97M | $-16.07M | $-16.31M |
| High Forecast | $-16.78M | $-16.19M | $-15.84M | $-15.27M | $-21.26M | $-19.88M | $-19.43M | $-15.33M | $-16.58M | $-16.07M | $-16.31M |
| Low Forecast | $-16.78M | $-16.19M | $-15.84M | $-15.27M | $-21.26M | $-19.88M | $-19.43M | $-21.49M | $-20.31M | $-16.07M | $-16.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JSPR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Jasper Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Jasper Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to JSPR last annual SG&A of $NaN (undefined).
Jasper Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-1.12 | $-1.08 | $-1.06 | $-1.02 | $-1.42 | $-1.32 | $-1.29 | $-1.23 | $-1.26 | $-1.07 | $-1.09 |
| High Forecast | $-1.12 | $-1.08 | $-1.06 | $-1.02 | $-1.42 | $-1.32 | $-1.29 | $-1.02 | $-1.11 | $-1.07 | $-1.09 |
| Low Forecast | $-1.12 | $-1.08 | $-1.06 | $-1.02 | $-1.42 | $-1.32 | $-1.29 | $-1.43 | $-1.35 | $-1.07 | $-1.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Jasper Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JSPR previous annual EPS of $NaN (undefined).
Jasper Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | $1.04 | $7.00 | 573.08% | Buy |
| EPIX | ESSA Pharma | $1.72 | $9.50 | 452.33% | Hold |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| LYRA | Lyra Therapeutics | $0.17 | $0.50 | 194.12% | Hold |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.50 | $17.00 | 100.00% | Buy |
| JSPR | Jasper Therapeutics | $20.43 | $34.75 | 70.09% | Buy |
| DSGN | Design Therapeutics | $5.80 | $9.67 | 66.72% | Buy |
| EWTX | Edgewise Therapeutics | $31.44 | $45.00 | 43.13% | Buy |
| HOOK | HOOKIPA Pharma | $3.00 | $3.00 | - | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |